Quarterly ResultJul 29, 2026, 07:06 AM
Bausch + Lomb Q2 Revenue $1.394B, +9%; Raises FY26 Guidance
AI Summary
Bausch + Lomb Corporation announced strong second-quarter 2026 financial results, with total revenue increasing 9% to $1.394 billion. The company significantly improved its GAAP net loss to $14 million and reported Adjusted EBITDA of $241 million. Reflecting this performance, Bausch + Lomb raised its full-year 2026 revenue and Adjusted EBITDA guidance. The company also shared positive topline results from a pivotal clinical study for its enVista Beyond™ investigational IOL.
Key Highlights
- Total revenue for Q2 2026 was $1.394 billion, up 9% (8% constant currency) YoY.
- GAAP net loss attributable to Bausch + Lomb was $14 million, improved from $62 million loss in Q2 2025.
- Adjusted EBITDA (non-GAAP) reached $241 million, an increase of $50 million YoY.
- Full-year 2026 revenue guidance raised to $5.440B - $5.540B.
- Full-year 2026 Adjusted EBITDA guidance raised to $1.025B - $1.075B.
- Surgical segment revenue grew 19% to $256 million.
- Pharmaceuticals segment revenue increased 15% to $354 million.
- enVista Beyond IOL pivotal study met co-primary effectiveness endpoints.
Price Impact
More from BLCO